Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) has seen a stock price increase of over 3%, currently trading at 15.53 HKD with a transaction volume of 5.21 million HKD, following the announcement of early clinical research results for three CDK inhibitors [1] Group 1: Company Developments - On October 21, Tongyuan Kang Pharmaceutical-B announced that its board is pleased to present early clinical research results for three key drugs in the CDK inhibitor field: TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302 (CDK4/6i) [1] - The results were showcased in poster format at the European Society for Medical Oncology (ESMO) annual meeting, which is one of the most influential academic events in the oncology field [1] Group 2: Industry Context - The ESMO 2025 annual meeting is scheduled to take place from October 17-21, 2025, in Berlin, Germany, attracting top experts and scholars to discuss clinical challenges and share cutting-edge advancements [1]

Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) has seen a stock price increase of over 3%, currently trading at 15.53 HKD with a transaction volume of 5.21 million HKD, following the announcement of early clinical research results for three CDK inhibitors at the ESMO 2025 conference [1] Company Summary - On October 21, Tongyuan Kang Pharmaceutical-B announced that its board is pleased to present early clinical research results for three key drugs in the cyclin-dependent kinase inhibitor (CDKi) field: TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302 (CDK4/6i) [1] - The results were showcased in poster format at the European Society for Medical Oncology (ESMO) 2025 conference, which is scheduled to take place from October 17-21, 2025, in Berlin, Germany [1] - ESMO is recognized as one of the most influential academic events in the oncology field, attracting top experts and providing a platform for discussing clinical challenges and sharing cutting-edge advancements [1]